MIRA PHARMACEUTICALS, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
MIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrated dose-dependent systemic exposure and rapid oral absorption, de-risking dose selection and supporting advancement toward GLP toxicology studies and IND-enabling development. No specific dollar amounts, share counts, or milestone dates beyond the announcement (August 6, 2026) were disclosed.
Why this rating
Preclinical data de-risks development path for obesity candidate in early-stage pipeline; modest progress relative to $16M market cap, but validates lead program and supports financing/partnership prospects
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.